HUP0202515A2 - Mezoprogesztogének (progeszteron receptor modulátorok) alkalmazása női fogamzásgátló gyógyszer komponenseként - Google Patents

Mezoprogesztogének (progeszteron receptor modulátorok) alkalmazása női fogamzásgátló gyógyszer komponenseként

Info

Publication number
HUP0202515A2
HUP0202515A2 HU0202515A HUP0202515A HUP0202515A2 HU P0202515 A2 HUP0202515 A2 HU P0202515A2 HU 0202515 A HU0202515 A HU 0202515A HU P0202515 A HUP0202515 A HU P0202515A HU P0202515 A2 HUP0202515 A2 HU P0202515A2
Authority
HU
Hungary
Prior art keywords
progesterone receptor
mesoprogestins
component
female
receptor modulators
Prior art date
Application number
HU0202515A
Other languages
English (en)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of HUP0202515A2 publication Critical patent/HUP0202515A2/hu
Publication of HUP0202515A3 publication Critical patent/HUP0202515A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya mezoprogesztogének alkalmazása női fogamzásgátlógyógyszerek előállítására, női fogamzásgátlásra alkalmasgyógyszerkészítmények, és eljárás női fogamzásgátlásra, amelynek soránvalamely mezoprogesztogén hatékony mennyiségét adagolják a fogamzásellen védekezni kívánó nőnek. Adott esetben a mezoprogesztogénösztrogénnel kombinálható. A mezoprogesztogének olyan vegyületkéntdefiniálhatók, amelyek a progeszteron receptorra (PR) in vivo agonistaés antagonista hatást egyaránt kifejtenek. Ó
HU0202515A 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives HUP0202515A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31
PCT/IB2000/002053 WO2001026603A2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Publications (2)

Publication Number Publication Date
HUP0202515A2 true HUP0202515A2 (hu) 2002-12-28
HUP0202515A3 HUP0202515A3 (en) 2004-06-28

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202515A HUP0202515A3 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Country Status (28)

Country Link
EP (1) EP1605949A2 (hu)
JP (1) JP2003511399A (hu)
KR (1) KR20020038745A (hu)
CN (1) CN1384748A (hu)
AR (1) AR025455A1 (hu)
AU (1) AU781835B2 (hu)
BG (1) BG106441A (hu)
BR (1) BR0013711A (hu)
CA (1) CA2383650A1 (hu)
CO (1) CO5190694A1 (hu)
CZ (1) CZ2002707A3 (hu)
EA (1) EA006805B1 (hu)
EE (1) EE200200103A (hu)
HR (1) HRP20020265A2 (hu)
HU (1) HUP0202515A3 (hu)
IL (1) IL148415A0 (hu)
LT (1) LT5001B (hu)
LV (1) LV12940B (hu)
MX (1) MXPA02002186A (hu)
NO (1) NO20020998L (hu)
NZ (1) NZ517470A (hu)
PE (1) PE20010579A1 (hu)
PL (1) PL353994A1 (hu)
SI (1) SI20853A (hu)
SK (1) SK2982002A3 (hu)
UA (1) UA77150C2 (hu)
WO (1) WO2001026603A2 (hu)
YU (1) YU13902A (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ES2273061T3 (es) * 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
SV2006002165A (es) * 2004-07-07 2006-05-09 Wyeth Corp Regimenes y kits de progestina ciclica ref. am101677
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
NZ595790A (en) * 2009-04-14 2013-11-29 Hra Pharma Lab Method for on-demand contraception
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
EP0559240B1 (en) * 1987-09-24 2001-12-05 Jencap Research Limited Contraceptive packages containing oestrogen and progestin
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429398C2 (de) 1994-08-09 1997-09-11 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE59511071D1 (de) * 1994-10-24 2007-01-25 Schering Ag Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
KR20000022189A (ko) * 1996-06-25 2000-04-25 에프.지.엠. 헤르만스;이.에이치. 리링크 프로제스토젠-항프로제스토젠 섭생
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
WO2000066590A2 (en) * 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
JP2003511399A (ja) 2003-03-25
CN1384748A (zh) 2002-12-11
AU3215001A (en) 2001-04-23
CO5190694A1 (es) 2002-08-29
BR0013711A (pt) 2002-05-07
PE20010579A1 (es) 2001-06-04
HRP20020265A2 (en) 2004-02-29
LT2002035A (lt) 2002-10-25
WO2001026603A3 (en) 2002-01-17
KR20020038745A (ko) 2002-05-23
NO20020998D0 (no) 2002-02-28
NZ517470A (en) 2004-03-26
SI20853A (sl) 2002-10-31
NO20020998L (no) 2002-03-14
EA200200284A1 (ru) 2002-10-31
EE200200103A (et) 2003-04-15
AU781835B2 (en) 2005-06-16
PL353994A1 (en) 2003-12-15
LV12940B (en) 2003-06-20
BG106441A (bg) 2002-09-30
LT5001B (lt) 2003-03-25
AR025455A1 (es) 2002-11-27
EP1605949A2 (en) 2005-12-21
EA006805B1 (ru) 2006-04-28
MXPA02002186A (es) 2002-09-02
HUP0202515A3 (en) 2004-06-28
WO2001026603A2 (en) 2001-04-19
IL148415A0 (en) 2002-09-12
CA2383650A1 (en) 2001-04-19
UA77150C2 (en) 2006-11-15
SK2982002A3 (en) 2002-07-02
CZ2002707A3 (cs) 2002-11-13
YU13902A (sh) 2006-01-16

Similar Documents

Publication Publication Date Title
Mishell Jr et al. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol andd-norgestrel
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
HK1109586A1 (en) Slow release estradiol-progesterone formulation
HUP0204349A2 (en) Novel topical oestroprogestational compositions with systemic effect
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
IL122432A0 (en) Transdermal patch for preventing ovulation
HUP0303182A2 (hu) Gyógyászati készítmények
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
HUP0402651A2 (hu) Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények és egységcsomagok
HUP0202515A2 (hu) Mezoprogesztogének (progeszteron receptor modulátorok) alkalmazása női fogamzásgátló gyógyszer komponenseként
MY122216A (en) New vaccine and method of use
HUP9900612A2 (hu) Új hormonális gyógyászati készítmények, valamint a készítmények alkalmazása ösztrogénpótlásra
HUP9904508A2 (hu) Egy ösztrogén vegyületet és egy progesztatív vegyületet tartalmazó hormonkészítmény
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
Bygdeman et al. Medical termination of early pregnancy: the Swedish experience
YU14002A (sh) Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja
WO2004011029A3 (en) Pharmaceutical compositions for penis enlargement
Csapo et al. Menstrual induction in preference to abortion
HUP0202460A2 (hu) A mezoprogesztinek (progeszteron-receptor-modulátorok), mint hormonpótlásos kezelésre alkalmas készítmények komponensei
Lello et al. Clinical trial of a monophasic estroprogestin oral formulation containing 20 μg ethinyl estradiol and 75 μg gestodene
Moggia et al. Evaluation of the contraceptive efficacy of quingestanol acetate (W 4540) when administered as an oral low-dose conraceptive in the puerperium
WO2000078298A3 (en) Programming ovulation by administering estrogen such as estradiol
Robb-Nicholson By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?
Dumont et al. Contraception in teenage girls: practical aspects